RNTX
Rein Therapeutics Inc.
NASDAQ · Healthcare · Medical - Pharmaceuticals · US
$0.89
+5.39%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
$76.70M
MomentumView details →
1D Return
+5.39%
YTD Return
−24.56%
RSI (14)
60.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
Market Cap
$76.70M
RSI (14)
60.2
MomentumView details →
1D Return
+5.39%
YTD Return
−24.56%
SummaryUpdated Jun 1, 2026
Rein Therapeutics Inc. (NASDAQ:RNTX) is a clinical-stage biopharmaceutical company founded in 2001 by a team of scientists including Gregory L. Verdine, Rosana Kapeller, and Loren David Walensky. Based in Austin, Texas, the company went public in June 2017 and focuses on developing novel therapeutic approaches for treating cancer and other diseases. Rein Therapeutics represents the growing field of precision oncology, where treatments are designed to target specific molecular pathways involved in cancer development and progression.
Similar companies
Latest newsMore news →
Rein Therapeutics reported its financial results for the second quarter ended June 30, 2026.21d agoRein Therapeutics announced publication of first-in-human clinical data for LTI-03 in Nature Communications, supporting its ongoing Phase 2 RENEW trial for idiopathic pulmonary fibrosis.31d agoRein Therapeutics announced that its Phase 2 RENEW clinical trial is now open and enrolling patients across all five planned countries.45d ago